References
- Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5(1):11. doi: 10.1186/1750-1172-5-11.
- Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155–167. doi: 10.1016/S0140-6736(17)31822-6.
- Cappellini MD, Farmakis D, Porter J, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT). 4th ed. Nicosia (Cyprus): Thalassaemia International Federation; 2021 [Internet]. 2021 [cited 23 August 2023]. Available from: https://www.thalassemia.org/wp-content/uploads/2021/06/TIF-2021-Guidelines-for-Mgmt-of-TDT.pdf.
- Brousse V, Badens C, Quignot N, et al. PRO58 clinical and economic burden of transfusion-dependent beta-thalassemia in France: a retrospective analysis of the French National Health Data System (SNDS). Value Health. 2019;22(3):S851. doi: 10.1016/j.jval.2019.09.2388.
- Donze C, Benoit A, Thuret I, et al. β-Thalassemia in childhood: current state of health in a high-income country. Br J Haematol. 2023;201(2):334–342. doi: 10.1111/bjh.18631.
- Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the systeme national d‘information interregimes de l‘Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149–S167. doi: 10.1016/j.respe.2017.05.004.
- Baronciani D, Angelucci E, Potschger U, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010. Bone Marrow Transplant. 2016;51(4):536–541. doi: 10.1038/bmt.2015.293.
- Pinto VM, Poggi M, Russo R, et al. Management of the aging beta-thalassemia transfusion-dependent population - The Italian experience. Blood Rev. 2019;38:100594. doi: 10.1016/j.blre.2019.100594.
- Udeze C, Evans KA, Yang Y, et al. Economic and clinical burden of managing transfusion-dependent β-thalassemia in the United States. J Med Econ. 2023;26(1):924–932. doi: 10.1080/13696998.2023.2235928.
- World Health Organization (WHO) [Internet]. The Global Health Observatory: life expectancy at birth (years); 2020. [cited December 2020]. Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/life-expectancy-at-birth-(years.).
- Institut national d‘études démographiques (INED) [Internet]. Life expectancy at birth and at 65 years; 2023. [cited January 2023]. Available from: https://www.ined.fr/en/everything_about_population/data/france/deaths-causes-mortality/life-expectancy/.
- The World Bank [Internet]. Life expectancy at birth (years); 2023. [cited October 2023]. Available from: https://genderdata.worldbank.org/indicators/sp-dyn-le-00-in/.
- Farmakis D, Porter J, Taher A, et al. 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Hemasphere. 2022;6(8):e732. doi: 10.1097/HS9.0000000000000732.
- Taher AT, Cappellini MD. How I manage medical complications of β-thalassemia in adults. Blood. 2018;132(17):1781–1791. doi: 10.1182/blood-2018-06-818187.
- Drahos J, Boateng-Kuffour A, Calvert M, et al. Sustained Humanistic Burden and Work Impact in Adults with Transfusion-Dependent Beta-Thalassemia (TDT): Results from a Global Longitudinal Survey [abstract]. Value Health. 2023;26(6):S317. Abstract PCR29. doi: 10.1016/j.jval.2023.03.1809.
- Shah F, Telfer P, Velangi M, et al. Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent beta-thalassaemia in the United Kingdom: A mixed methods observational study. EJHaem. 2021;2(4):738–749. doi: 10.1002/jha2.282.